Evidence map›Paper›PMID 35984658›Full record

Trial reportJAMA network open2022

Assessment of Outcomes From 1-Year Surveillance After Detection of Early Gastric Cancer Among Patients at High Risk in Japan.

Yoshinobu Yamamoto, Naohiro Yoshida, Tomonori Yano, Takahiro Horimatsu, Noriya Uedo, Noboru Kawata, Hiromitsu Kanzaki, Shinichiro Hori, Kenshi Yao, Seiichiro Abe and 7 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in JAMA network open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. [Importance of Early Surveillance Endoscopy in Patients at a High Risk of Gastric Cancer].The Korean journal of helicobacter and upper gastrointestinal research · 2023
    Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 14 institutions in 1 country.

Yoshinobu YamamotoDepartment of Gastrointestinal Oncology, Hyogo Cancer Center, Akashi, Hyogo, Japan.
Naohiro YoshidaDepartment of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan.
Tomonori YanoDepartment of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Chiba, Japan.
Takahiro HorimatsuDepartment of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan.
Noriya UedoDepartment of Gastrointestinal Oncology, Osaka International Cancer Institute, Osaka, Osaka, Japan.
Noboru KawataDivision of Endoscopy, Shizuoka Cancer Center, Suntogun, Shizuoka, Japan.
Hiromitsu KanzakiDepartment of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Okayama, Japan.
Shinichiro HoriDepartment of Endoscopy, National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, Japan.
Kenshi YaoDepartment of Endoscopy, Fukuoka University Chikushi Hospital, Chikushino, Fukuoka, Japan.
Seiichiro AbeEndoscopy Division, National Cancer Center Hospital, Chuo, Tokyo, Japan.
Chikatoshi KatadaDepartment of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan.
Chizu YokoiEndoscopy Division, National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan.
Ken OhataDepartment of Gastroenterology, NTT Medical Center Tokyo, Shinagawa, Tokyo, Japan.
Hisashi DoyamaDepartment of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa, Japan.
Kenichi YoshimuraDepartment of Biostatistics, Hiroshima University Hospital, Hiroshima University, Hiroshima, Japan.
Hideki IshikawaDepartment of Molecular-Targeting Cancer Prevention, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Manabu MutoDepartment of Therapeutic Oncology, Kyoto University Graduate School of Medicine, Kyoto, Kyoto, Japan.
Ishikawa Prefectural Central Hospital · JPKyoto University · JPNational Cancer Center Hospital East · JPFukuoka University · JPHiroshima University Hospital · JPHyogo Prefectural Cancer Center · JPKitasato University · JPKyoto Prefectural University of Medicine · JPNational Center for Global Health and Medicine · JPNTT Medical Center · JPOkayama University · JPOsaka Medical Center for Cancer and Cardiovascular Diseases · JPShikoku Cancer Center · JPShizuoka Cancer Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Importance: Single endoscopic examination often misses early gastric cancer (GC), even when both high-definition white light imaging and narrow-band imaging are used. It is unknown whether new GC can be detected approximately 1 year after intensive index endoscopic examination. Objective: To examine whether new GC can be detected approximately 1 year after intensive index endoscopic examination using both white light and narrow-band imaging. Design, Setting, and Participants: This case-control study was a preplanned secondary analysis of a randomized clinical trial involving 4523 patients with a high risk of GC who were enrolled between October 1, 2014, and September 22, 2017. Data were analyzed from December 26, 2019, to April 21, 2021. Participants in the clinical trial received index endoscopy to detect early GC via 2 examinations of the entire stomach using white light and narrow-band imaging. The duration of follow-up was 15 months. The secondary analysis included 107 patients with newly detected GC (case group) and 107 matched patients without newly detected GC (control group) within 15 months after index endoscopy. Interventions: Surveillance endoscopy was scheduled between 9 and 15 months after index endoscopy. If new lesions suspected of being early GC were detected during surveillance endoscopy, biopsies were obtained to confirm the presence of cancer. Main Outcomes and Measures: The primary end point was the rate of new GC detected within 15 months after index endoscopy. The main secondary end point was identification of risk factors associated with new GC detected within 15 months after index endoscopy. Results: Among 4523 patients (mean [SD] age, 70.6 [7.5] years; 3527 men [78.0%]; all of Japanese ethnicity) enrolled in the clinical trial, 4472 received index endoscopy; the rate of early GC detected on index endoscopy was 3.0% (133 patients). Surveillance endoscopy was performed in 4146 of 4472 patients (92.7%) who received an index endoscopy; the rate of new GC detected within 15 months after index endoscopy was 2.6% (107 patients). Among 133 patients for whom early GC was detected during index endoscopy, 110 patients (82.7%) received surveillance endoscopy within 15 months after index endoscopy; the rate of newly detected GC was 10.9% (12 patients). For the secondary analysis of risk factors associated with newly detected GC, characteristics were well balanced between the 107 patients included in the case group vs the 107 patients included in the matched control group (mean [SD] age, 71.7 [7.2] years vs 71.8 [7.0] years; 94 men [87.9%] in each group; 82 patients [76.6%] vs 87 patients [81.3%] with a history of gastric neoplasm). Multivariate analysis revealed that the presence of open-type atrophic gastritis (odds ratio, 6.00; 95% CI, 2.25-16.01; P < .001) and early GC detection by index endoscopy (odds ratio, 4.67; 95% CI, 1.08-20.21; P = .04) were independent risk factors associated with new GC detection. Conclusions and Relevance: In this study, the rate of new GC detected by surveillance endoscopy approximately 1 year after index endoscopy was similar to that of early GC detected by index endoscopy. These findings suggest that 1-year surveillance is warranted for patients at high risk of GC.

Indexed as

Stomach NeoplasmsAgedCase-Control StudiesEarly Detection of CancerHumansJapanMaleNarrow Band Imaging

Identifiers

PMID35984658
PMCPMC9391963
OpenAlexW4292367700

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.